COMMUNIQUÉS West-GlobeNewswire

Novonesis delivers strong half-year results and increases full-year outlook

27/08/2024 - 16:34

In the first half of 2024, Novonesis delivered 7% organic sales growth with an adjusted EBITDA margin at 35.3%. Following strong first half-year performance, Novonesis increases its full-year organic sales outlook from [...]

Interim Report H1 2024

27/08/2024 - 16:30

H1 organic pro forma sales growth at 7%, with pro forma adjusted EBITDA margin at 35.3%. Full-year outlook increased. H1 organic pro forma sales growth of 7% and 8% on IFRS reported basis. Q2 organic pro forma sales [...]

Novonesis increases outlook for full year 2024

27/08/2024 - 16:29

Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half. The 2024 outlook is increased to [...]

AMN Healthcare Introduces Strategic Partnership Solutions – First In-House Full-Service Language Service Solution for Health Systems

27/08/2024 - 16:07

DALLAS, Aug. 27, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Language Services (AMN LS), a leading provider of language solutions for the healthcare industry, today announced the launch of its newest offering – Strategic [...]

Ultrahuman Launches Ring AIR at Verizon, Expands its US Footprint

27/08/2024 - 16:00

Ultrahuman Ring AIR Becomes the First Smart Ring Available at Verizon New York , Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ultrahuman , a pioneer in wearable technology, is thrilled to announce the launch of the Ultrahuman Ring [...]

Key Highlights of Lighthouse Fusion

27/08/2024 - 15:00

Multidisciplinary Clinical Expertise MISHAWAKA, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lighthouse Autism Center, a leading provider of autism support and education, is proud to announce a significant expansion to its [...]

NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024

27/08/2024 - 15:00

CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]

GLUCOTRACK ANNOUNCES NEW VICE PRESIDENT OF CLINICAL OPERATIONS

27/08/2024 - 15:00

Glucotrack expands leadership team with clinical trial expertise for the continuous blood glucose monitor for people with diabetes Rutherford, NJ, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“ [...]

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

27/08/2024 - 14:45

Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging Patients treated with bezisterim experienced 2 to 4 years age deceleration advantage compared to [...]

CervoMed to Participate in Upcoming Investor Conferences

27/08/2024 - 14:30

BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s management will [...]

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York

27/08/2024 - 14:30

LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a [...]

Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference

27/08/2024 - 14:30

THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how [...]

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

27/08/2024 - 14:30

The Congresswoman representing Georgia’s 7th district in the U.S. House of Representatives toured Femasys’ facilities to gain a better understanding of our advancements for women’s reproductive health ATLANTA, Aug. 27, [...]

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

27/08/2024 - 14:01

Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA ) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking [...]

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

27/08/2024 - 14:00

JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today [...]

Korro to Participate in Upcoming September Investor and Scientific Conferences

27/08/2024 - 14:00

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly [...]

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

27/08/2024 - 14:00

PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a [...]

Spectral AI Completes Burn Center Enrollment for U.S. Burn Pivotal Study

27/08/2024 - 14:00

Milestone Achievement Advances Commercialization Timeline for DeepView™ System for Burn Indication DALLAS, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an [...]

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

27/08/2024 - 14:00

ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) BOSTON and LONDON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Centessa [...]